Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Anoro Ellipta Needs CV Postmarket Study, FDA Panel Says In Endorsement

This article was originally published in The Pink Sheet Daily

Executive Summary

Pulmonary-Allergy Drugs Advisory Committee votes in favor of what could become the first-approved LAMA/LABA combo for COPD but wants postmarket safety study in patients with more severe cardiovascular disease.

Advertisement

Related Content

Signs Of R&D Progress For GSK, Though China Overhang Remains
Advair Bioequivalence Guidance Falls Short of GSK’s Requests
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
Forest Tudorza Pressair Approval For COPD Includes Post-marketing CV Safety Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076219

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel